Diagnosis of EVALI in the COVID-19 era – The Lancet

As of Feb 18, 2020, a total of 2807 cases of e-cigarette, or vaping, product use-associated lung injury (EVALI) and 68 attributed deaths have been reported to the US Centers for Disease Control and Prevention.1Centers for Disease Control and Prevention
Outbreak of lung injury associated with the use of e-cigarette, or vaping products. Diagnostic criteria for EVALI consists of a mixture of non-specific systemic symptoms (eg, fever, chills, and vomiting) and respiratory symptoms (eg, shortness of breath, cough, chest pain, pnoea, and hypoxia), along with detection of lung opacities on imaging. Diagnosis also depends on identifying a history of vaping and careful exclusion of alternative conditions.2Layden JE Ghinai I Pray I et al.Pulmonary illness related to e-cigarette use in Illinois and Wisconsin—final report.<i aria-hidden="true"